Compare MATH & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MATH | IPHA |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | Hong Kong | France |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.4M | 174.2M |
| IPO Year | N/A | 2019 |
| Metric | MATH | IPHA |
|---|---|---|
| Price | $2.66 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 115.0K | ★ 565.1K |
| Earning Date | 12-05-2025 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $44,567,257.00 | $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | N/A | $43.84 |
| P/E Ratio | $6.63 | ★ N/A |
| Revenue Growth | ★ 165.86 | N/A |
| 52 Week Low | $0.88 | $1.41 |
| 52 Week High | $4.17 | $3.51 |
| Indicator | MATH | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 52.17 |
| Support Level | $2.75 | $1.81 |
| Resistance Level | $3.03 | $1.91 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 30.43 | 50.00 |
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.